Premature ejaculation (PE) has been known as one of the most common male sexual dysfunction.
Until now dapoxetine is the only approved medical treatment option and there is no second
line therapy in case of no-response or refuse to dapoxetine, a comprehensive evaluation of
the factors that lead to dropout is needed especially in a real-practice setting.
With this background, investigators are going to assesse the discontinuation rate of
dapoxetine treatment in patients with PE and the reasons for discontinuation in a clinical
setting throughout a follow-up period of 2 years.